메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

TCL CSOT Unveils "2025 Eye-Care Technology White Paper", Setting New Benchmarks for Natural-Light Display Standards

SUZHOU, China, Nov. 25, 2025 -- TCL China Star Optoelectronics Technology (TCL CSOT), a global leader in advanced display technologies and a subsidiary of TCL Technology (000100.SZ), in collaboration with the National Engineering Research Center for Ophthalmology & Optometry of Wenzhou Medical University in China, and leading industry partners including Lenovo, CVTE, TAL Education, the China Institute of Standardization, SGS, officially released the "2025 Eye-Care Technology White Paper" (the White Paper) at the TCL CSOT Display Health Industry Seminar. The White
- 김갑성 기자
- 2025-11-25 18:01
메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp-erzs) 관련 신규 데이터 발표

모구 형질세포양 수지상세포 종양(BPDCN) 환자들에게 중요한 발견을 담은 2건의 구두 발표를 포함하여 총 5개의 초록에 걸친 데이터 공개 BPDCN은 피부, 골수, 혈액에 주로 영향을 미치는 매우 공격적인 희귀 혈액암 이탈리아 피렌체 및 뉴욕, 2025년 11월 25일 -- 세계적인 제약·진단 기업인 메나리니 그룹(Menarini Group)과 메나리니 그룹의 전액 출자 자회사이자 암 환자들에게 혁신적인 종양 치료제를 제공하는 데 주력하는 스템라인 테라퓨틱스(Stemline Therapeutics)가 오늘 12월 6일부터 9일까지 올랜도에서 열리는 미국혈액학회(American Society of Hematology, ASH) 연례 학술대회에서 ELZONRIS® (tagraxofusp-erzs) 관련 신규 데이터를 발표한다고 밝혔다. 발표 중에는 tagraxofusp, azacitidine, venetoclax 3제 요법 결과를 다루는 구두 세션이 포함된다. 이 요법은 높은 반응률과 이식 전 단계(bride to transplant) 도달률, 그리고 내약성을 함께 보여 모구 형질세
- 김갑성 기자
- 2025-11-25 17:44
볼피 로세 메나리니: 2025-2026 시즌 출전 준비를 마친 '환상적인 10인'

메나리니가 후원하는 이탈리아 휠체어 농구팀이 이탈리아 언론과 대중에게 공식적으로 얼굴을 알렸다. 그들이 이탈리아 세리에 A와 유로컵 3에서 마주하게 될 난관이 서서히 윤곽을 드러내고 있다. 피렌체, 이탈리아, 2025년 11월 25일 -- 10명의 다국적 선수가 나이와 경험의 차이는 있지만, 이탈리아와 유럽 무대에서 선한 영향을 미치겠다는 열정으로 똘똘 뭉쳤다. 2025/2026 시즌 개막전을 마친 뒤, FIPIC 세리에 A(FIPIC Serie A) 챔피언십과 유로컵 3(Eurocup 3)에 참가할 볼피 로세 메나리니(Volpi Rosse Menarini) 휠체어 농구팀의 새로운 선수 명단이 공식적으로 발표되었다. 올해 코치진은 홈경기와 원정경기 모두에서 배경이 저마다 다른 선수들로 구성된 팀을 이끌게 된다. 볼피 로세 메나리니 팀은 스페인부터 핀란드, 스웨덴, 프랑스, 이탈리아, 브라질에 이르기까지 다양한 국적의 선수로 구성된 진정한 다국적 팀이다. 이 팀은 현재 이탈리아 챔피언십 경기를 앞두고 있다. 이탈리아 챔피언십은 2026년 3월 12일부터 15일까지 암스테르담에서 열리는 유로컵 3에 앞서 반
- 황정호 기자
- 2025-11-25 17:05
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by
- 김갑성 기자
- 2025-11-25 17:00
FROM MEDICAL SUPPLIER TO MULTI-INDUSTRY LEADER: LIVINGSTONE INTERNATIONAL'S UNIQUE GROWTH STRATEGY

SYDNEY, Nov. 25, 2025 -- One of Australia's largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries. Livingstone International supplies more than 65,000 essential health, hygiene, education, beauty, and hospitality products to industries including aged care, schools and universities, hair and skin clinics, pharmacy, dental, mining, and government. Livingstone International Managing Director, Daniel Linn, said the company has no
- 김갑성 기자
- 2025-11-25 05:00
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization

[ 메디채널 김갑성 기자 ] The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating ad
- 김갑성 기자
- 2025-11-25 00:30
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy and NEW YORK, Nov. 24, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology
- 김갑성 기자
- 2025-11-24 23:34
Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release

- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer's disease. "While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease," said Joanne Pike, DrPH, Alzheimer's A
- 김갑성 기자
- 2025-11-24 23:19
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season

Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public in Italy. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon FLORENCE, Italy, Nov. 24, 2025 -- Ten international talents, differing in both age and experience but united by the desire to make a difference, both in Italy and Europe. After the opening match of the 2025/2026 season, the new roster of the Volpi Rosse Menarini wheelchair basketball team was officially presented today, ready to start competing in the FIPIC Serie A championsh
- 황정호 기자
- 2025-11-24 22:40
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, in
- 김갑성 기자
- 2025-11-24 22:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분